Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1985 1
1987 1
1989 1
1990 2
1994 1
1995 4
1996 3
1997 3
1998 4
1999 14
2000 8
2001 13
2002 18
2003 24
2004 23
2005 15
2006 22
2007 17
2008 23
2009 24
2010 23
2011 22
2012 21
2013 23
2014 7
2015 14
2016 13
2017 9
2018 8
2019 9
2020 11
2021 12
2022 14
2023 4
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

369 results

Results by year

Filters applied: . Clear all
Page 1
Mirtazapine as Appetite Stimulant in Patients With Non-Small Cell Lung Cancer and Anorexia: A Randomized Clinical Trial.
Arrieta O, Cárdenas-Fernández D, Rodriguez-Mayoral O, Gutierrez-Torres S, Castañares D, Flores-Estrada D, Reyes E, López D, Barragán P, Soberanis Pina P, Cardona AF, Turcott JG. Arrieta O, et al. JAMA Oncol. 2024 Mar 1;10(3):305-314. doi: 10.1001/jamaoncol.2023.5232. JAMA Oncol. 2024. PMID: 38206631 Clinical Trial.
OBJECTIVES: To assess the effect of mirtazapine on appetite and energy consumption in patients with advanced non-small cell lung cancer (NSCLC). ...Fats intake was significantly higher in patients in the mirtazapine group (14.5 g vs 0.7 g; P = .02) after 8 weeks. Th …
OBJECTIVES: To assess the effect of mirtazapine on appetite and energy consumption in patients with advanced non-small cell lung canc …
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design.
Rush AJ, Fava M, Wisniewski SR, Lavori PW, Trivedi MH, Sackeim HA, Thase ME, Nierenberg AA, Quitkin FM, Kashner TM, Kupfer DJ, Rosenbaum JF, Alpert J, Stewart JW, McGrath PJ, Biggs MM, Shores-Wilson K, Lebowitz BD, Ritz L, Niederehe G; STAR*D Investigators Group. Rush AJ, et al. Control Clin Trials. 2004 Feb;25(1):119-42. doi: 10.1016/s0197-2456(03)00112-0. Control Clin Trials. 2004. PMID: 15061154 Clinical Trial.
Level 2 and 2A participants are eligible for random assignment to two switch options (mirtazapine or nortriptyline) and to two augment options (lithium or thyroid hormone) added to the primary antidepressant (citalopram, bupropion, sertraline, or venlafaxine) (level 3). Th …
Level 2 and 2A participants are eligible for random assignment to two switch options (mirtazapine or nortriptyline) and to two augmen …
Mirtazapine in Cancer-Associated Anorexia and Cachexia: A Double-Blind Placebo-Controlled Randomized Trial.
Hunter CN, Abdel-Aal HH, Elsherief WA, Farag DE, Riad NM, Alsirafy SA. Hunter CN, et al. J Pain Symptom Manage. 2021 Dec;62(6):1207-1215. doi: 10.1016/j.jpainsymman.2021.05.017. Epub 2021 May 26. J Pain Symptom Manage. 2021. PMID: 34051293 Clinical Trial.
Mirtazapine was associated with significantly less increase in depressive symptoms and higher prevalence of somnolence. The change in other outcomes did not differ significantly between mirtazapine and placebo. CONCLUSION: Mirtazapine 15mg at night for 28 day …
Mirtazapine was associated with significantly less increase in depressive symptoms and higher prevalence of somnolence. The change in …
Maintenance or Discontinuation of Antidepressants in Primary Care.
Lewis G, Marston L, Duffy L, Freemantle N, Gilbody S, Hunter R, Kendrick T, Kessler D, Mangin D, King M, Lanham P, Moore M, Nazareth I, Wiles N, Bacon F, Bird M, Brabyn S, Burns A, Clarke CS, Hunt A, Pervin J, Lewis G. Lewis G, et al. N Engl J Med. 2021 Sep 30;385(14):1257-1267. doi: 10.1056/NEJMoa2106356. N Engl J Med. 2021. PMID: 34587384 Clinical Trial.
Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their current antidepressant therapy (maintenance group) or to taper and discontinue such therapy with the use of matching placebo (discontinuatio …
Patients who had received citalopram, fluoxetine, sertraline, or mirtazapine were randomly assigned in a 1:1 ratio to maintain their …
Study of mirtazapine for agitated behaviours in dementia (SYMBAD): a randomised, double-blind, placebo-controlled trial.
Banerjee S, High J, Stirling S, Shepstone L, Swart AM, Telling T, Henderson C, Ballard C, Bentham P, Burns A, Farina N, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Tabet N. Banerjee S, et al. Lancet. 2021 Oct 23;398(10310):1487-1497. doi: 10.1016/S0140-6736(21)01210-1. Lancet. 2021. PMID: 34688369 Free PMC article. Clinical Trial.
The number of controls with adverse events (65 [64%] of 102 controls) was similar to that in the mirtazapine group (67 [66%] of 102 participants receiving mirtazapine). ...INTERPRETATION: This trial found no benefit of mirtazapine compared with placebo, and w …
The number of controls with adverse events (65 [64%] of 102 controls) was similar to that in the mirtazapine group (67 [66%] of 102 p …
Relationship between circulating mitochondrial DNA and microRNA in patients with major depression.
Ogata H, Higasa K, Kageyama Y, Tahara H, Shimamoto A, Takekita Y, Koshikawa Y, Nonen S, Kato T, Kinoshita T, Kato M. Ogata H, et al. J Affect Disord. 2023 Oct 15;339:538-546. doi: 10.1016/j.jad.2023.07.073. Epub 2023 Jul 17. J Affect Disord. 2023. PMID: 37467797 Free article. Clinical Trial.
The patients were randomly assigned to receive either selective serotonin reuptake inhibitors (SSRI) or mirtazapine. Their therapeutic efficacy over four weeks was evaluated in relation to miRNAs correlated with ccf-mtDNA copy number. ...Of these five miRNAs, miR-6068 and …
The patients were randomly assigned to receive either selective serotonin reuptake inhibitors (SSRI) or mirtazapine. Their therapeuti …
Efficacy of Augmentation of Cognitive Behavioral Therapy With Transcranial Direct Current Stimulation for Depression: A Randomized Clinical Trial.
Aust S, Brakemeier EL, Spies J, Herrera-Melendez AL, Kaiser T, Fallgatter A, Plewnia C, Mayer SV, Dechantsreiter E, Burkhardt G, Strauß M, Mauche N, Normann C, Frase L, Deuschle M, Böhringer A, Padberg F, Bajbouj M. Aust S, et al. JAMA Psychiatry. 2022 Jun 1;79(6):528-537. doi: 10.1001/jamapsychiatry.2022.0696. JAMA Psychiatry. 2022. PMID: 35442431 Free PMC article. Clinical Trial.
They were either not receiving medication or were receiving a stable regimen of antidepressant medication (selective serotonin reuptake inhibitor and/or mirtazapine). A total of 148 women and men underwent randomization: 53 individuals were assigned to CBT alone (group 0), …
They were either not receiving medication or were receiving a stable regimen of antidepressant medication (selective serotonin reuptake inhi …
A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer's disease and agitated behaviours: the HTA-SYMBAD trial.
Banerjee S, Farina N, Henderson C, High J, Stirling S, Shepstone L, Fountain J, Ballard C, Bentham P, Burns A, Fox C, Francis P, Howard R, Knapp M, Leroi I, Livingston G, Nilforooshan R, Nurock S, O'Brien J, Price A, Thomas AJ, Swart AM, Telling T, Tabet N. Banerjee S, et al. Health Technol Assess. 2023 Oct;27(23):1-108. doi: 10.3310/VPDT7105. Health Technol Assess. 2023. PMID: 37929672 Free PMC article. Clinical Trial.
Mean difference placebo-mirtazapine (-1.74, 95% confidence interval -7.17 to 3.69; p = 0.53). Harms: The number of controls with adverse events (65/102, 64%) was similar to the mirtazapine group (67/102, 66%). However, there were more deaths in the mirtazapine …
Mean difference placebo-mirtazapine (-1.74, 95% confidence interval -7.17 to 3.69; p = 0.53). Harms: The number of controls with adve …
COMBINED MIRTAZAPINE AND SSRI TREATMENT OF PTSD: A PLACEBO-CONTROLLED TRIAL.
Schneier FR, Campeas R, Carcamo J, Glass A, Lewis-Fernandez R, Neria Y, Sanchez-Lacay A, Vermes D, Wall MM. Schneier FR, et al. Depress Anxiety. 2015 Aug;32(8):570-9. doi: 10.1002/da.22384. Epub 2015 Jun 26. Depress Anxiety. 2015. PMID: 26115513 Free PMC article. Clinical Trial.
This study aimed to assess acceptability of combined sertraline plus mirtazapine treatment for PTSD and to estimate its effect size relative to sertraline plus placebo. ...Combined treatment with an SSRI plus mirtazapine in PTSD deserves additional study as initial …
This study aimed to assess acceptability of combined sertraline plus mirtazapine treatment for PTSD and to estimate its effect size r …
Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study.
Kato M, Baba H, Takekita Y, Naito M, Koshikawa Y, Bandou H, Kinoshita T. Kato M, et al. Eur J Clin Pharmacol. 2023 Nov;79(11):1515-1524. doi: 10.1007/s00228-023-03563-8. Epub 2023 Sep 13. Eur J Clin Pharmacol. 2023. PMID: 37700038 Clinical Trial.
OBJECTIVE: Mirtazapine and SSRIs are widely prescribed as first-line agents for late-life depression. ...In contrast, somnolence was less common in late-life depression with mirtazapine. CONCLUSION: The potential usefulness of mirtazapine in elderly patients …
OBJECTIVE: Mirtazapine and SSRIs are widely prescribed as first-line agents for late-life depression. ...In contrast, somnolence was …
369 results